0001213900-26-053208
SEC filingZhongchao Inc. is a Cayman Islands holding company using a VIE structure to consolidate PRC operating entities providing healthcare education, training, and patient management services through MDMOOC platform. This F-1 filing supports a $12M best-efforts offering of Units amid declining revenues and Nasdaq compliance challenges.
Zhongchao Inc. operates as a Cayman holding company using a VIE structure to circumvent PRC restrictions on foreign ownership in value-added telecom services, consolidating Zhongchao Shanghai's healthcare education platform MDMOOC. This enables exposure to PRC operations providing online/offline medical training, patient management for oncology/rare diseases, and formerly patented drug sales (discontinued June 2025). Revenues fell 28% YoY to $11.4M in 2025 amid project optimization and drug sales cessation, with net loss widening to $5.8M driven by $3.7M share-based compensation and credit losses. Gross margins contracted to 45% from 56% due to fixed costs amid revenue decline. Cash reserves stand at $8.1M, supporting operations without immediate liquidity crisis, though PRC repatriation hurdles limit dividend potential.
The $12M best-efforts offering of 5.56M Units at $2.16 (Nasdaq close Apr 30, 2026) includes highly dilutive Warrants with cashless/zero-price exercise (floor $0.432), potentially issuing up to 50M shares if price drops, exacerbating dilution concerns amid recent Nasdaq bid price compliance via 1-for-8 reverse split. CEO Weiguang Yang controls 99.5% voting via Class B shares (1,000:1 ratio), enabling controlled company exemptions from Nasdaq independence rules. Proceeds target working capital amid revenue contraction.
PRC regulatory risks dominate: VIE enforceability untested in court; CSRC post-offering filing mandatory under 2023 Trial Measures, with non-compliance risking fines/repatriation blocks. No cybersecurity review needed (<1M users), but broad CAC discretion persists. Dividend repatriation constrained by SAFE rules, statutory reserves (10% profits), and forex controls. Nasdaq delisting threat lingers despite compliance, given dilution overhang.
Strategically, MDMOOC's professional database and content moat position it in China's growing CME market, but competition erodes margins. Discontinuing unprofitable drug sales refocuses on core services (94% 2025 revenue), yet customer concentration (top-4: 61%) and 33 employees signal scale challenges. Investor focus: VIE/governance risks, dilution mechanics, regulatory filings, and path to revenue stabilization.